The Danish pharmaceutical company Novo Nordisk is putting a preliminary plug in its million payments to American politicians.
It comes as a consequence of last week’s riots in the United States, where Trump supporters stormed Congress and five people lost their lives in the same connection.
It writes Jyllands-Posten’s business media, Finans.
Basically, companies are not allowed to donate money to political candidates in the United States. In return, they must do so indirectly through a so-called Political Action Committee (PAC).
Under U.S. law, companies are allowed to organize their own PACs, to which, for example, senior executives, employees, and shareholders may donate.
“We have put donations from our political action committee on hold, and we will now look at how we relate to political donations in the future,” Novo writes in an email according to Finans.
In the same email, the pharmaceutical company points out that it “condemns” the attack on Congress.
“Despite the events, we are delighted that the nation’s democratic process prevailed and that Congress continued its efforts to approve the outcome of the 2020 US presidential election,” Novo wrote in the email.
According to Finans, the total donations from Novos PAC in 2020 were just over 2.3 million kroner with a small preponderance of money for the Democrats.
According to Finans, Lundbeck, another large Danish pharmaceutical company, is currently considering its contributions to American politicians.
Last week’s attack on Congress came after President Donald Trump called on protesters to march on Capitol Hill and protest the outcome of the presidential election.
From various quarters, the president has since been criticized for boosting the political unrest that has existed since the presidential election last year.
The next president, Joe Biden, is set to take over from Donald Trump in a week.
/ ritzau /
*The article has been translated based on the content of www.berlingske.dk by www.berlingske.dk. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!